Korea adds Pergoveris pen to reimbursement rolls, vial already covered
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
DealPulse Signal
The Beats
Analysis
The Briefs
Korea adds Pergoveris pen to reimbursement rolls, vial already covered
CDA-AMC reverses course, backs Leqembi’s first ruling content still undisclosed
Nine More Drugmakers Signed MFN Deals. The Coalition Formed to Fight Them Did Not.
Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.
3 of 1,357 Cleared AI Devices Have Public Outcome Trials. The Study Has No Non-AI Comparator.